Overview

Since 2008 in Europe, masitinib is registered in a canine cancer called mast cell tumor, the most common cutaneous cancer in dogs. The drug is marketed by AB Science under the brand Masivet® (MA numbers EU/2/08/087/003 and EU/2/08/087/002).
 
The Summary of Product Characteristics is available here.